Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

Overview of attention for article published in The Lancet, November 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

So far, Altmetric has seen 1 blog post.

Results of a phase III study published in The Lancet shows that more than 40% of patients with Tuberous Sclerosis Complex (TSC…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.